The background to finerenone and the FIDELIO CKD trial was covered in a post on the 11th of July. Last week, there was a coordinated presentation at the American Society of Nephrology Kidney Week and a publication in the New England Journal of Medicine of the details of the the FIDELIO CKD. In a nutshell,… Continue reading The fine details of the finerenone Fidelio CKD trial – A new drug to slow CKD
The much awaited outcome of the DAPA-CKD (Dapagliflozin And Prevention of Adverse Outcomes in Chronic Kidney Disease ) trial was presented on 30 August 2020 at the ESC (European Society of Cardiology) Congress 2020 by Prof H. Heerspink. Dapagliflozin is an SGLT2 ( Sodium-Glucose Co-transporter 2) inhibitor being used,so far, in the treatment of type… Continue reading Ground breaking results from key trial : DAPA CKD
The Summary A Chinese led research team say a blood test – called PanSeer – detects cancer in 95% of asymptomatic individuals who later receive a diagnosis. “We demonstrated that five types of cancer can be detected through a DNA methylation-based blood test up to four years before conventional diagnosis,” the team writes in the… Continue reading ‘Liquid Biopsy’ Detects Cancer Years Before Symptoms
Big announcement from Bayer on Thursday 9 June. Are we on the verge of a major step forward in the pharmacological fight against diabetic nephropathy? We all know diabetic nephropathy (DN) is by far the most common cause of end-stage renal disease in Mauritius and worldwide. The inhibition of the renin-angiotensin-aldosterone system (RAAS) has been… Continue reading A Fine Renal Breakthrough?
In the search for a treatment for COVID-19, attention has turned to preexisting drugs in the hope to reduce the lead time in finding a cure. Hydroxychloroquine (HCQ), chloroquine (CQ) and macrocodes (MC) are all known to have antiviral effects (first two through endosomal acidification) in other viral diseases and there were promising results in… Continue reading Hydroxychloroquine for Covid-19: Review of the Literature so far